This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Bartonellosis Therapeutics Market

Market Insights on Bartonellosis Therapeutics covering sales outlook, demand forecast & up-to-date key trends

Bartonellosis Therapeutics Market by Drug Class, Route of Administration, Distribution Channel, End Users, Region | Forecast 2023 to 2033

Bartonellosis Therapeutics Market Snapshot (2023 to 2033)

The global bartonellosis therapeutics market size is expected to surpass an impressive valuation of US$ 1.2 Billion in 2023 and is projected to exhibit a CAGR of 12% from 2023 to 2033, reaching US$ 3.72 Billion.

Bartonellosis is a bacterial infection caused by the genus Bartonella. Carrión's disease, trench fever, cat scratch illness, bacillary angiomatosis, peliosis hepatis, prolonged bacteremia, endocarditis, chronic lymphadenopathy, and neurological disorders are all induced by Bartonella species. Bartonella henselae is the most prevalent trigger of bartonellosis in the United States.

People who are homeless are more likely to become infected with B. Quintana because they have restricted access to shower and laundry amenities. Infection with B. Quintana occurs worldwide. As a result, this factor is propelling overall growth.

Report Attribute

Details

Expected Market Value (2023)

US$ 1.2 Billion

Anticipated Forecast Value (2033)

US$ 3.72 Billion

Projected Growth Rate (2023 to 2033)

12% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Bartonellosis Therapeutics Demand Analysis vs. Forecast 2023 to 2033

The presence of a robust product pipeline, as well as upcoming launches propelled the market growth. One of the key determinants in the market is the rising Research and Development investments by prevalent vendors for orphan-developing drugs and innovative product offerings. In 2021, there were approximately 791 prospective orphan drug applicants in clinical trials for the treatment of rare diseases, as per Pharmaceutical Research and Manufacturers of America. As a result, the market for bartonellosis therapeutics grew during the historical era.

Over the forecast period the market for bartonellosis therapeutics is expected to grow because, without therapies, the fatality rate from this illness ranges from 40 to 90%. With the pathogen preserved in the body, bartonellosis enters a dormant stage, followed by reoccurrence and the evolution of a chronic phase, the Peruvian wart.

Which are Some Prominent Drivers of the Bartonellosis Therapeutics Market?

Development of More Effective Antibiotics to Generate Widespread Opportunities for Growth

Antibiotic demand is rapidly expanding owing to an increase in cat scratch disease cases and soaring market growth. The increased prevalence of the disease is captivating government bodies to spend on Research and Development approaches and fuel the creation of breakthrough antibiotics therapy, in addition to encouraging regulatory policies to accelerate the authorization and funding for research. For example, BARDA, in collaboration with the US government, has assisted several organizations in the development of novel treatments for bartonellosis.

The development of novel SMA Drugs to Drive Sales Growth

A multidisciplinary approach based on breakthrough proposals for the creation of novel SMA drugs to address unmet medical needs in rare therapeutic strategies is expected to drive market growth. In June 2021, for example, the European expert group on orphan drug incentives released a set of policy initiatives to address unmet healthcare needs in rare conditions.

This proposed policy involves a review of the EMA's pharma approach and orphan drug laws to encourage Spending on orphan drugs. In addition, basic research on patient access, new therapeutic challenges, and governmental authorizations are key areas highlighted in the proposed policies. During the forecast timeframe, such favorable government approaches are predicted to encourage market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

A rise in Multidrug-Resistant Bacterial Infections may have a Restraining Influence on Market Expansion

Pharmaceutical companies are forming partnerships to develop new therapeutic strategies to minimize the financial strain of the process of drug development. However, an increase in multidrug-resistant bacterial infections may put a damper on the industry.

Region-Wise Insights

What Makes North America the Largest Market for Bartonellosis Therapeutics?

Increasing Number of CSD cases in the United States to drive Growth

North America's market is highly subject to regulation and has a robust healthcare system. The emergence of communicable disease cases and government health expenditures in the region is a significant factor propelling the market in North America. To regulate cat scratch diseases, the US government is implementing a variety of measures, including antibiotic stewardship initiatives and encouraging Research and development for therapeutic approaches.

The United States. Stray cats are more inclined to be infected with B. henselae than pets. The majority of CSD cases in the United States occur in the fall and winter. Thus it is expected to propel market growth in North America. According to Future Market Insights, the USA is likely to experience a CAGR of 11.7% with regard to bartonellosis therapeutics.

Why is Asia Pacific Considered a Lucrative Region for the Bartonellosis Therapeutics Market?

Government Initiatives to foster Orphan Drugs Development Programs to propel Growth

During the projected timeline, Asia Pacific is projected to be the fastest emerging market. The region's expansion can be attributed to government interventions to assist orphan disorder patients. For example, in July 2022, the Indian government oriented national and state governments to ensure the successful implementation of insurance programs created for the treatment of people undergoing orphan diseases.

This indicator offers an opportunity for healthcare practitioners to develop excellent quality orphan medications for the administration while also generating revenue. As a result, this factor is anticipated to propel the bartonellosis therapeutics market in the upcoming decade. FMI expects the APAC market for bartonellosis therapeutics to accumulate a revenue share of 33% in 2023.

What Makes Europe the Largest Market for Bartonellosis Therapeutics?

Europe to drive market owing to increased demand for Cutting-Edge Medical Services

Europe is expected to expand significantly during the projected timeframe, 2023-2033. The market's expansion can be mainly ascribed to the region's burgeoning demand for cutting-edge medical services, which is fueled by the region's population explosion in countries such as the United Kingdom, France, Germany, Sweden, the Netherlands, Italy, and Russia.

As per World Bank statistics, the total population in the United Kingdom and France in 2021 was 67,326,569, and 67,499,343, respectively. As a result, the Bartonellosis market is anticipated to grow further. A CAGR of 11.5% is projected for the bartonellosis therapeutics market in Europe.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

By End-User, Which Segment is Projected to Lead the Market?

Treatment for Bartonellosis to be Maximum across Hospitals

During the evaluation period, the hospital is expected to be the fastest-growing segment owing to the high hospitalization rate of SMA. As per the report, hospitals are likely to account for 40% of all bartonellosis therapeutics in 2023 and beyond.

Because of the high well construction and equipment facilities, hospitals treat the vast bulk of bartonellosis patients. As a result, the hospital segment is anticipated to account for a sizable share of the market.

Which Segment under Drug Class Will Account for the Highest Market Growth?

Demand for Antibiotics to be at the Pinnacle

Infectious diseases are always treated with antibiotics and medications. Given the possibility of supplementary salmonellosis, ciprofloxacin or chloramphenicol should be used in conjunction with a beta-lactam antibiotic to cure the disease swiftly.

As a result, the demand for antibiotics medicine is rapidly increasing, propelling the segment's growth, and expected to capture a revenue share of over 50% in 2023 and beyond.

Start-ups offering Therapeutics for Bartonellosis

  • Galaxy Diagnostics, established in 2007, is an initial infectious disease diagnostic company. Galaxy Diagnostics began testing on animals in 2009 and human testing in 2011 and has improved testing methodologies over the years. The company provides Bartonella tests for cats and dogs, and the tests are also obtainable through a collaboration with Idexx Laboratories.

Market Competition

Key players in the Bartonellosis Therapeutics market are Abbott, Allergan, Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., Novartis AG, Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Viatris, Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, AstraZeneca, Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company.

  • Bayer Healthcare Animal Health has been working with veterinarians, physicians, and specialists on bartonellosis diseases all over the world. In addition, Bayer Animal Health provides products such as Seresto, which protects pets from fleas and prevents bartonellosis. This is the latest in a series of innovative anti-parasite product lines from one of the world's foremost animal medical companies.
  • In July 2021, GlaxoSmithKline Plc. collaborated with Alector to develop and commercialize two clinical-stage, potential first-in-class monoclonal antibodies named AL001 and AL101. These antibodies are designed to evaluate progranulin levels, a key regulator of immune activity in the brain assisting in managing neurodegenerative disorders. The collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s Research and Development focus on the science of the immune system and human genetics, proven late-stage drug development capabilities, and global footprint.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 1.2 Billion

Market Value in 2033

US$ 3.72 Billion

Growth Rate

CAGR of 12% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in US$ Million and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Drug Class
  • Route of Administration
  • Distribution Channel
  • End Users
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Key Countries Profiled

  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Singapore
  • Thailand
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Abbott
  • Allergan
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Viatris
  • Sun Pharmaceutical Industries Ltd.
  • Lilly
  • Aurobindo Pharma
  • Lupin
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • Bristol-Myers Squibb Company

Customization

Available Upon Request

Key Segments Profiled in the Bartonellosis Therapeutics Market Industry Survey 

By Drug Class:

  • Antibiotics
  • NSAIDs
  • Others

By Route of Administration:

  • Oral
  • Intravenous
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End Users:

  • Hospitals
  • Clinics
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

According to Future Market Insights, the bartonellosis treatment market is expected to be valued at US$ 1.2 Billion in 2023

From 2023 to 2033, bartonellosis treatment worth is expected to grow at a CAGR of 12%

As of 2033, the bartonellosis treatment market is likely to reach US$ 3.72 Billion

The bartonellosis therapeutics landscape in the U.S is expected to grow at an 11.7% CAGR from 2023-2033

In the Asia Pacific, bartonellosis therapeutics is expected to account for 1/3rd of all bacterial infections treatment in 2023

Europe is most likely to experience a growth rate of 11.5% with regard to bartonellosis therapeutics from 2023-2033

Antibiotics are expected to constitute 50% of all bartonellosis treatments

GlaxoSmithKline Plc., Abbott Laboratories, Sanofi SA and Pfizer Inc. are some key bartonellosis therapeutics providers

Table of Content

1. Executive Summary | Bartonellosis Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand to side Trends

    1.3. Supply to side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023 to 2033

        4.2.1. Y to o to Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Antibiotics

        5.3.2. NSAIDs

        5.3.3. Others

    5.4. Y to o to Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Intravenous

        6.3.3. Others

    6.4. Y to o to Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Retail Pharmacy

        7.3.3. Online Pharmacy

    7.4. Y to o to Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End to Users

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By End to Users, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End to Users, 2023 to 2033

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Others

    8.4. Y to o to Y Growth Trend Analysis By End to Users, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End to Users, 2023 to 2033

9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia Pacific

        9.3.5. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

        10.2.5. By End to Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

        10.3.5. By End to Users

    10.4. Key Takeaways

11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

        11.2.5. By End to Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

        11.3.5. By End to Users

    11.4. Key Takeaways

12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. UK

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

        12.2.5. By End to Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

        12.3.5. By End to Users

    12.4. Key Takeaways

13. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

            13.2.1.4. Singapore

            13.2.1.5. Thailand

            13.2.1.6. Indonesia

            13.2.1.7. Australia

            13.2.1.8. New Zealand

            13.2.1.9. Rest of Asia Pacific

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

        13.2.5. By End to Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

        13.3.5. By End to Users

    13.4. Key Takeaways

14. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

        14.2.5. By End to Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

        14.3.5. By End to Users

    14.4. Key Takeaways

15. Key Countries Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Route of Administration

            15.1.2.3. By Distribution Channel

            15.1.2.4. By End to Users

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Route of Administration

            15.2.2.3. By Distribution Channel

            15.2.2.4. By End to Users

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Route of Administration

            15.3.2.3. By Distribution Channel

            15.3.2.4. By End to Users

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Route of Administration

            15.4.2.3. By Distribution Channel

            15.4.2.4. By End to Users

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Route of Administration

            15.5.2.3. By Distribution Channel

            15.5.2.4. By End to Users

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Route of Administration

            15.6.2.3. By Distribution Channel

            15.6.2.4. By End to Users

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Route of Administration

            15.7.2.3. By Distribution Channel

            15.7.2.4. By End to Users

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Route of Administration

            15.8.2.3. By Distribution Channel

            15.8.2.4. By End to Users

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Route of Administration

            15.9.2.3. By Distribution Channel

            15.9.2.4. By End to Users

    15.10. China

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Route of Administration

            15.10.2.3. By Distribution Channel

            15.10.2.4. By End to Users

    15.11. Japan

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Route of Administration

            15.11.2.3. By Distribution Channel

            15.11.2.4. By End to Users

    15.12. South Korea

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Route of Administration

            15.12.2.3. By Distribution Channel

            15.12.2.4. By End to Users

    15.13. Singapore

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Route of Administration

            15.13.2.3. By Distribution Channel

            15.13.2.4. By End to Users

    15.14. Thailand

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Route of Administration

            15.14.2.3. By Distribution Channel

            15.14.2.4. By End to Users

    15.15. Indonesia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Route of Administration

            15.15.2.3. By Distribution Channel

            15.15.2.4. By End to Users

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Route of Administration

            15.16.2.3. By Distribution Channel

            15.16.2.4. By End to Users

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Route of Administration

            15.17.2.3. By Distribution Channel

            15.17.2.4. By End to Users

    15.18. GCC Countries

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Route of Administration

            15.18.2.3. By Distribution Channel

            15.18.2.4. By End to Users

    15.19. South Africa

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Route of Administration

            15.19.2.3. By Distribution Channel

            15.19.2.4. By End to Users

    15.20. Israel

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Route of Administration

            15.20.2.3. By Distribution Channel

            15.20.2.4. By End to Users

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Route of Administration

        16.3.4. By Distribution Channel

        16.3.5. By End to Users

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Abbott

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Allergan

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. F. Hoffmann to La Roche Ltd.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. GlaxoSmithKline plc

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Merck Sharp & Dohme Corp.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Novartis AG

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Sanofi

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Pfizer Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Teva Pharmaceutical Industries Ltd.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Bayer AG

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Viatris

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Sun Pharmaceutical Industries Ltd.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

        17.1.13. Lilly

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

        17.1.14. Aurobindo Pharma

            17.1.14.1. Overview

            17.1.14.2. Product Portfolio

            17.1.14.3. Profitability by Market Segments

            17.1.14.4. Sales Footprint

            17.1.14.5. Strategy Overview

                17.1.14.5.1. Marketing Strategy

        17.1.15. Lupin

            17.1.15.1. Overview

            17.1.15.2. Product Portfolio

            17.1.15.3. Profitability by Market Segments

            17.1.15.4. Sales Footprint

            17.1.15.5. Strategy Overview

                17.1.15.5.1. Marketing Strategy

        17.1.16. AstraZeneca

            17.1.16.1. Overview

            17.1.16.2. Product Portfolio

            17.1.16.3. Profitability by Market Segments

            17.1.16.4. Sales Footprint

            17.1.16.5. Strategy Overview

                17.1.16.5.1. Marketing Strategy

        17.1.17. Johnson & Johnson Private Limited

            17.1.17.1. Overview

            17.1.17.2. Product Portfolio

            17.1.17.3. Profitability by Market Segments

            17.1.17.4. Sales Footprint

            17.1.17.5. Strategy Overview

                17.1.17.5.1. Marketing Strategy

        17.1.18. Boehringer Ingelheim International GmbH

            17.1.18.1. Overview

            17.1.18.2. Product Portfolio

            17.1.18.3. Profitability by Market Segments

            17.1.18.4. Sales Footprint

            17.1.18.5. Strategy Overview

                17.1.18.5.1. Marketing Strategy

        17.1.19. Dr. Reddy’s Laboratories Ltd.,

            17.1.19.1. Overview

            17.1.19.2. Product Portfolio

            17.1.19.3. Profitability by Market Segments

            17.1.19.4. Sales Footprint

            17.1.19.5. Strategy Overview

                17.1.19.5.1. Marketing Strategy

        17.1.20. Bristol to Myers Squibb Company

            17.1.20.1. Overview

            17.1.20.2. Product Portfolio

            17.1.20.3. Profitability by Market Segments

            17.1.20.4. Sales Footprint

            17.1.20.5. Strategy Overview

                17.1.20.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Value (US$ Mn) Forecast by Region, 2018 to 2033

Table 2: Global Value (US$ Mn) Forecast by Drug Class, 2018 to 2033

Table 3: Global Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033

Table 5: Global Value (US$ Mn) Forecast by End to Users, 2018 to 2033

Table 6: North America Value (US$ Mn) Forecast by Country, 2018 to 2033

Table 7: North America Value (US$ Mn) Forecast by Drug Class, 2018 to 2033

Table 8: North America Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033

Table 9: North America Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033

Table 10: North America Value (US$ Mn) Forecast by End to Users, 2018 to 2033

Table 11: Latin America Value (US$ Mn) Forecast by Country, 2018 to 2033

Table 12: Latin America Value (US$ Mn) Forecast by Drug Class, 2018 to 2033

Table 13: Latin America Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033

Table 14: Latin America Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033

Table 15: Latin America Value (US$ Mn) Forecast by End to Users, 2018 to 2033

Table 16: Europe Value (US$ Mn) Forecast by Country, 2018 to 2033

Table 17: Europe Value (US$ Mn) Forecast by Drug Class, 2018 to 2033

Table 18: Europe Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033

Table 19: Europe Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033

Table 20: Europe Value (US$ Mn) Forecast by End to Users, 2018 to 2033

Table 21: Asia Pacific Value (US$ Mn) Forecast by Country, 2018 to 2033

Table 22: Asia Pacific Value (US$ Mn) Forecast by Drug Class, 2018 to 2033

Table 23: Asia Pacific Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033

Table 24: Asia Pacific Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033

Table 25: Asia Pacific Value (US$ Mn) Forecast by End to Users, 2018 to 2033

Table 26: MEA Value (US$ Mn) Forecast by Country, 2018 to 2033

Table 27: MEA Value (US$ Mn) Forecast by Drug Class, 2018 to 2033

Table 28: MEA Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033

Table 29: MEA Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033

Table 30: MEA Value (US$ Mn) Forecast by End to Users, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Mn) by Drug Class, 2023 to 2033

Figure 2: Global Value (US$ Mn) by Route of Administration, 2023 to 2033

Figure 3: Global Value (US$ Mn) by Distribution Channel, 2023 to 2033

Figure 4: Global Value (US$ Mn) by End to Users, 2023 to 2033

Figure 5: Global Value (US$ Mn) by Region, 2023 to 2033

Figure 6: Global Value (US$ Mn) Analysis by Region, 2018 to 2033

Figure 7: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Y to o to Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Value (US$ Mn) Analysis by Drug Class, 2018 to 2033

Figure 10: Global Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 11: Global Y to o to Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 12: Global Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033

Figure 13: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 14: Global Y to o to Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 15: Global Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033

Figure 16: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 17: Global Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 18: Global Value (US$ Mn) Analysis by End to Users, 2018 to 2033

Figure 19: Global Value Share (%) and BPS Analysis by End to Users, 2023 to 2033

Figure 20: Global Y to o to Y Growth (%) Projections by End to Users, 2023 to 2033

Figure 21: Global Attractiveness by Drug Class, 2023 to 2033

Figure 22: Global Attractiveness by Route of Administration, 2023 to 2033

Figure 23: Global Attractiveness by Distribution Channel, 2023 to 2033

Figure 24: Global Attractiveness by End to Users, 2023 to 2033

Figure 25: Global Attractiveness by Region, 2023 to 2033

Figure 26: North America Value (US$ Mn) by Drug Class, 2023 to 2033

Figure 27: North America Value (US$ Mn) by Route of Administration, 2023 to 2033

Figure 28: North America Value (US$ Mn) by Distribution Channel, 2023 to 2033

Figure 29: North America Value (US$ Mn) by End to Users, 2023 to 2033

Figure 30: North America Value (US$ Mn) by Country, 2023 to 2033

Figure 31: North America Value (US$ Mn) Analysis by Country, 2018 to 2033

Figure 32: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Y o to Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Value (US$ Mn) Analysis by Drug Class, 2018 to 2033

Figure 35: North America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 36: North America Y o to Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 37: North America Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033

Figure 38: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 39: North America Y o to Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 40: North America Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033

Figure 41: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: North America Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: North America Value (US$ Mn) Analysis by End to Users, 2018 to 2033

Figure 44: North America Value Share (%) and BPS Analysis by End to Users, 2023 to 2033

Figure 45: North America Y o to Y Growth (%) Projections by End to Users, 2023 to 2033

Figure 46: North America Attractiveness by Drug Class, 2023 to 2033

Figure 47: North America Attractiveness by Route of Administration, 2023 to 2033

Figure 48: North America Attractiveness by Distribution Channel, 2023 to 2033

Figure 49: North America Attractiveness by End to Users, 2023 to 2033

Figure 50: North America Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Value (US$ Mn) by Drug Class, 2023 to 2033

Figure 52: Latin America Value (US$ Mn) by Route of Administration, 2023 to 2033

Figure 53: Latin America Value (US$ Mn) by Distribution Channel, 2023 to 2033

Figure 54: Latin America Value (US$ Mn) by End to Users, 2023 to 2033

Figure 55: Latin America Value (US$ Mn) by Country, 2023 to 2033

Figure 56: Latin America Value (US$ Mn) Analysis by Country, 2018 to 2033

Figure 57: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Y o to Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Value (US$ Mn) Analysis by Drug Class, 2018 to 2033

Figure 60: Latin America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 61: Latin America Y o to Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 62: Latin America Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033

Figure 63: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 64: Latin America Y to o to Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 65: Latin America Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033

Figure 66: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 67: Latin America Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 68: Latin America Value (US$ Mn) Analysis by End to Users, 2018 to 2033

Figure 69: Latin America Value Share (%) and BPS Analysis by End to Users, 2023 to 2033

Figure 70: Latin America Y o to Y Growth (%) Projections by End to Users, 2023 to 2033

Figure 71: Latin America Attractiveness by Drug Class, 2023 to 2033

Figure 72: Latin America Attractiveness by Route of Administration, 2023 to 2033

Figure 73: Latin America Attractiveness by Distribution Channel, 2023 to 2033

Figure 74: Latin America Attractiveness by End to Users, 2023 to 2033

Figure 75: Latin America Attractiveness by Country, 2023 to 2033

Figure 76: Europe Value (US$ Mn) by Drug Class, 2023 to 2033

Figure 77: Europe Value (US$ Mn) by Route of Administration, 2023 to 2033

Figure 78: Europe Value (US$ Mn) by Distribution Channel, 2023 to 2033

Figure 79: Europe Value (US$ Mn) by End to Users, 2023 to 2033

Figure 80: Europe Value (US$ Mn) by Country, 2023 to 2033

Figure 81: Europe Value (US$ Mn) Analysis by Country, 2018 to 2033

Figure 82: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Europe Y to o to Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Europe Value (US$ Mn) Analysis by Drug Class, 2018 to 2033

Figure 85: Europe Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 86: Europe Y to o to Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 87: Europe Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033

Figure 88: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 89: Europe Y to o to Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 90: Europe Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033

Figure 91: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 92: Europe Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 93: Europe Value (US$ Mn) Analysis by End to Users, 2018 to 2033

Figure 94: Europe Value Share (%) and BPS Analysis by End to Users, 2023 to 2033

Figure 95: Europe Y to o to Y Growth (%) Projections by End to Users, 2023 to 2033

Figure 96: Europe Attractiveness by Drug Class, 2023 to 2033

Figure 97: Europe Attractiveness by Route of Administration, 2023 to 2033

Figure 98: Europe Attractiveness by Distribution Channel, 2023 to 2033

Figure 99: Europe Attractiveness by End to Users, 2023 to 2033

Figure 100: Europe Attractiveness by Country, 2023 to 2033

Figure 101: Asia Pacific Value (US$ Mn) by Drug Class, 2023 to 2033

Figure 102: Asia Pacific Value (US$ Mn) by Route of Administration, 2023 to 2033

Figure 103: Asia Pacific Value (US$ Mn) by Distribution Channel, 2023 to 2033

Figure 104: Asia Pacific Value (US$ Mn) by End to Users, 2023 to 2033

Figure 105: Asia Pacific Value (US$ Mn) by Country, 2023 to 2033

Figure 106: Asia Pacific Value (US$ Mn) Analysis by Country, 2018 to 2033

Figure 107: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: Asia Pacific Y o to Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: Asia Pacific Value (US$ Mn) Analysis by Drug Class, 2018 to 2033

Figure 110: Asia Pacific Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 111: Asia Pacific Y o to Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 112: Asia Pacific Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033

Figure 113: Asia Pacific Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 114: Asia Pacific Y o to Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 115: Asia Pacific Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033

Figure 116: Asia Pacific Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 117: Asia Pacific Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 118: Asia Pacific Value (US$ Mn) Analysis by End to Users, 2018 to 2033

Figure 119: Asia Pacific Value Share (%) and BPS Analysis by End to Users, 2023 to 2033

Figure 120: Asia Pacific Y o to Y Growth (%) Projections by End to Users, 2023 to 2033

Figure 121: Asia Pacific Attractiveness by Drug Class, 2023 to 2033

Figure 122: Asia Pacific Attractiveness by Route of Administration, 2023 to 2033

Figure 123: Asia Pacific Attractiveness by Distribution Channel, 2023 to 2033

Figure 124: Asia Pacific Attractiveness by End to Users, 2023 to 2033

Figure 125: Asia Pacific Attractiveness by Country, 2023 to 2033

Figure 126: MEA Value (US$ Mn) by Drug Class, 2023 to 2033

Figure 127: MEA Value (US$ Mn) by Route of Administration, 2023 to 2033

Figure 128: MEA Value (US$ Mn) by Distribution Channel, 2023 to 2033

Figure 129: MEA Value (US$ Mn) by End to Users, 2023 to 2033

Figure 130: MEA Value (US$ Mn) by Country, 2023 to 2033

Figure 131: MEA Value (US$ Mn) Analysis by Country, 2018 to 2033

Figure 132: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: MEA Y o to Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: MEA Value (US$ Mn) Analysis by Drug Class, 2018 to 2033

Figure 135: MEA Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 136: MEA Y to o to Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 137: MEA Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033

Figure 138: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 139: MEA Y o to Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 140: MEA Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033

Figure 141: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 142: MEA Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 143: MEA Value (US$ Mn) Analysis by End to Users, 2018 to 2033

Figure 144: MEA Value Share (%) and BPS Analysis by End to Users, 2023 to 2033

Figure 145: MEA Y o to Y Growth (%) Projections by End to Users, 2023 to 2033

Figure 146: MEA Attractiveness by Drug Class, 2023 to 2033

Figure 147: MEA Attractiveness by Route of Administration, 2023 to 2033

Figure 148: MEA Attractiveness by Distribution Channel, 2023 to 2033

Figure 149: MEA Attractiveness by End to Users, 2023 to 2033

Figure 150: MEA Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Antibacterial Haemostatic Gels Market

Published : August 2021

Healthcare

Antibiotics Active Pharmaceutical Ingredient (API) Market

Published : February 2021

Healthcare

Topical Antibiotic Pharmaceuticals Market

Published : April 2016

Google translate

Bartonellosis Therapeutics Market